Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 710 participants.

Also called NCT07715929

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 710 participants (planned count) (from the registry)
Sponsor
Yunlong Wang (from the registry)
Registry
  • NCT NCT07715929
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07715929. Randomized; single masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2029-09-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
Acronym
TEAR-AF
Condition
Obesity & Overweight
Intervention (Drug)
Tirzepatide
Intervention (Behavioral)
Structured Lifestyle Intervention
Lead sponsor
Yunlong Wang (class: other)

Record details

Record id
cardio:ct-nct07715929
Content hash
5e74c03034a187281e339f0ae2aaf42e14bffe9127066d3b7afcd0036ee97236